Innovation in pharmaceuticals is not possible without Research & Development. Morepen driven by its passion for adhering to International quality standards has created an excellent in-house R&D center, focused on identifying and manufacturing high value added, complex new molecules for introduction in the generic market.

Sophisticated, state-of-the art instruments like HPLC, GC, FTIR, UV spectrophotometer are used for standardisation of manufacturing processes.

Key areas in which the company carries out R&D include:

  • Maximising utilisation of indigenous raw materials and imports substitution.

  • Development of novel drug delivery systems.

  • Development of products based on medicinal plants.

  • Development of safety and environment conservation methods.

  • Process and product development for existing and new products.

R & D Activities - Breaking fresh ground Patent rules are being strengthened globally and there is urgent need of development of non-infringing processes of bulk drugs to capture global market. MLL is world leader as an approved generic supplier of Loratadine due to development of non-infringing commercially viable and cost effective manufacturing processes for the same. R&D scientists are involved in the development of non-infringing process of Atorvastatin Calcium and Fluvastatin sodium (Cholesterol lowering agents), Ramipril (an antihypertensive agent), Citalopram hydrobromide (an anti depressant), Fexofenadine Hydrochloride (anti-allergic product) and Pioglitazone Hydrochloride (An antidiabitic), which are at advance stages.

Copyright © QuGen Inc. All rights reserved